Phrontline Biopharma, a China-based antibody‑drug conjugate (ADC) developer,
said it closed a Series A round of nearly $40m, bringing total new investment to
about $100m over the past year. The round was led by Yuanhe Origin and Decheng
Capital, with participation from Longpan Investment, Jifeng Capital, Mifang
Health Fund, Songqing Capital and Jianfa Emerging Investment; Dianshi Capital
served as exclusive financial adviser. Proceeds will accelerate clinical
development of the core pipeline, support IND filings for differentiated reserve
candidates, build a new payload platform and expand international collaborations
and capitalization efforts.
